Abiopharma

🔍 Martin Brad W (Executive)

Company: ATN International, Inc. (ATNI)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Acquired 27,048 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 127,366.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 27,048 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-03-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 27,048.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: The securities described are restricted stock units and will vest in four equal installments on each of March 17, 2027, 2028, 2029 and 2030. Upon vesting, Mr. Martin will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
• F2: Each performance-based RSU ("PSU") represents a contingent right to receive one share of the Issuer's common stock, subject to the achievement of pre-established relative total shareholder return ("TSR") goals that were set by the Compensation Committee of the Issuer's Board of Directors, based on comparing the Issuer's TSR relative to the TSR of the Russell 2000 Index, using the average closing price of the shares for the 40 days before and including each of the first and last days of the applicable performance period. The aggregate number of shares issued may range from zero (0) shares to 150% of the target number of shares reported in columns 7 and 9 of this report.
• F3: Between zero (0) and 150% of the PSUs will generally vest, if at all, as of the end of the performance period that begins on March 17, 2026, and ends on March 17, 2029.